Fierce Pharma May 17, 2024
Right on the heels of a similar move by Johnson & Johnson, GSK has agreed to sell the rest of its stake in the consumer healthcare business it spun out back in 2022.
Thursday, GSK revealed its intent to sell (PDF) its remaining 4.2% holding in Haleon, representing around 385 million shares. A day later, GSK said (PDF) the agreement raised proceeds of 1.248 billion pounds sterling ($1.58 billion).
The shares are being offered to institutional investors by Goldman Sachs and Bank of America Securities, the company said.
GSK completed the spinoff of its consumer health division—formerly a joint venture between the British pharma and Pfizer—in July 2022. At the time, GSK held a roughly 13% stake in Haleon,...
Today's Sponsors
Today's Sponsor